Stock AnalizPACS Group, Inc. PACS
Hospital/Nursing Management · IPO 2024 · data as of November 13, 2026
PACS Group, Inc. (PACS) is a healthcare company listed in the US with a market value of about $7.7B. In the twelve months to September 30, 2026 it had revenue of $5.7B and net income of $278M, a net margin of 4.9%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is future growth (5/5); the weakest is shareholder returns (1/5).
Key numbers: a P/E of 27.5, a price to free cash flow of 17.1, a 5-year average ROIC of 64%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 7% above the current price.
Score: 2.4 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year average ROIC above 12%
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Debt below 3 years of free cash flow
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $5.7B | $5.3B | $4.1B | $3.1B | $2.4B |
| Net income | $278M | $192M | $56M | $113M | $150M |
| Free cash flow | $448M | $299M | $301M | $18M | $70M |
| EPS (diluted) | $1.76 | $1.22 | $0.38 | $0.88 | $1.17 |
| Net margin | 4.9% | 3.6% | 1.4% | 3.6% | 6.2% |
| ROIC | — | 4.7% | 1.6% | 6.3% | 242.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $61.33, 27% above the current price; targets range from $57.00 to $67.00; the consensus rating is “Strong buy”; expected EPS is $2.62 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is PACS Group’s P/E ratio?
About 27.5, based on the last twelve months of diluted earnings per share (forward P/E about 17.5).
Is PACS Group stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 7% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does PACS Group pay a dividend?
Not currently.
Is PACS Group a good stock to buy?
We do not give buy or sell advice. PACS Group scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.